Esperion announced that the FDA has approved an updated LDL-cholesterol lowering indication for Nexletol and Nexlizet to include the treatment of primary hyperlipidemia as a qualifier for existing… read more.
People who live in neighborhoods with higher levels of poverty and unemployment are less likely to fill their heart-failure drug prescriptions than those living in wealthier areas, a… read more.
Medtronic plc announced that the FDA has approved the PulseSelect Pulsed Field Ablation (PFA) System for the treatment of both paroxysmal and persistent atrial fibrillation (AF). This is… read more.
Despite an end to the national public health emergency in May 2023, the use of telehealth remains high, with over 20% of American adults taking appointments online. These visits include… read more.
As the use of wearable technology grows, smart watches are marketed across the globe to consumers as a way to monitor health. For some, they’re told by these… read more.
Amgen announced new data reinforcing the safety and efficacy of Repatha (evolocumab) from the FOURIER Open Label Extension (OLE) [FOURIER-OLE] trial at the American Heart Association (AHA) Scientific… read more.
Medtronic plc announced that the FDA has approved the Symplicity Spyral renal denervation (RDN) system, also known as the Symplicity blood pressure procedure, for the treatment of hypertension…. read more.
The odds of prescribing the appropriate dose of statins—a medicine used to lower “bad” cholesterol levels—increased sixfold when automated referrals were made to pharmacy services, instead of relying… read more.
Patients treated with the investigative PCSK9 inhibitor recaticimab have achieved highly significant reducions in bad cholesterol, and they have done so with less frequent injections than patients treated… read more.
Low levels of Vitamin D have been shown to be associated with a higher risk of having a cardiac event, like a heart attack or stroke. For this… read more.
If pharmacists had a larger role in prescribing medications to control blood pressure, they could prevent more than 15 million heart attacks, nearly 8 million strokes and more… read more.
Edwards Lifesciences Corporation announced one-year results from CLASP IID, the first randomized controlled trial that directly compares two contemporary mitral transcatheter edge-to-edge repair (TEER) therapies, as well as… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
